I have read the prescribing information and it addresses the adjacent case but not this one.
I want a method I can write down and repeat, not a rule of thumb.
I would rather over-engineer this than discover a problem later, within reason.
Concretely, what should I do, and how would I know afterwards whether I did it right?
3 days past a due dose is 0.43 half-lives at the seven-day half-life this class runs on, which leaves about 74.3 per cent of that dose still circulating. One line of arithmetic: remaining fraction is one half raised to days over half-life, so 0.5^(3÷7) = 0.743. At 74.3 per cent you have not been off it in any meaningful sense. The interval stretched from 7 days to 10 and the trough went lower than usual; that is the whole of what happened. What the product label says and what the pharmacokinetics say are two different answers here, and the first is the one that governs. Restarting, holding or stepping down after a gap is decided under supervision, and nothing here is medical advice.
Answer first: it depends on the half-life and on how long ago the dose was due, and for a weekly agent the tolerance is much wider than people fear.
For a daily agent with a thirteen-hour half-life, a missed dose is a much larger proportional loss. The usual approach is to skip it and take the next scheduled one rather than doubling.
Set a recurring reminder tied to something you already do weekly. The commonest cause of a missed dose is not forgetting the drug but losing track of the day.
Published missed-dose guidance for the weekly agents in this class specifies a window of about five days, derived directly from the half-life.
Within about five days for a weekly agent, take it. Beyond that, skip and resume.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsThe honest answer is that a single missed weekly dose is not an event, and that two in a row starts to matter.
If more than two consecutive weekly doses are missed, tolerance to the gastrointestinal effects begins to fade and re-titration from a lower step becomes the sensible approach.
Never take two doses close together to compensate. The peak exposure is roughly doubled, and gastrointestinal tolerability tracks peak exposure closely.
Loss of tolerance during a treatment gap is documented and is the basis for re-titration after an interruption.
The caveat is that anyone on other glucose-lowering medication has an interaction question here that needs a prescriber.
To move your dosing day, move it later and keep three days between doses.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.